In our current study, we found that VP suppressed multiple targets, including AMOTL1, YAP1, and CTGF, which might serve as a desirable option to help GC patients to achieve satisfied therapeutic effects during chemotherapy. The gene discussed is CCN2; the disease is gastric cancer.